Cisplatin. A phase II evaluation in previously untreated patients with soft tissue sarcomas
- 1 March 1987
- Vol. 59 (5) , 884-886
- https://doi.org/10.1002/1097-0142(19870301)59:5<884::aid-cncr2820590504>3.0.co;2-k
Abstract
A Phase II trial of moderately high-dose cisplatin (120 mg/m2 with mannitol diuresis) was conducted in 26 previously untreated patients with soft tissue sarcomas. One partial response (major response rate, 4%) and two minor responses were seen. Severe nausea and vomiting and transient increases in the serum creatinine level were the most common side effects of treatment. Cisplatin has minimal activity as a single agent in patients with soft tissue sarcoma. Cancer 59:884-886, 1987.This publication has 5 references indexed in Scilit:
- Phase II trial of cisplatin (CPDD) in previously treated patients with advanced soft tissue sarcomaCancer, 1982
- CIS-DIAMMINEDICHLOROPLATINUM(II) ALONE AND IN COMBINATION IN THE TREATMENT OF TESTICULAR AND OTHER MALIGNANCIES1980
- E.O.R.T.C. phase II study of cisplatin in cyvadic-resistant soft tissue sarcomaPublished by Elsevier ,1979
- CIS-DICHLORODIAMMINEPLATINUM(II) IN METASTATIC SOFT-TISSUE SARCOMAS1979
- CIS-DICHLORODIAMMINEPLATINUM(II) IN ADVANCED SOFT-TISSUE AND BONY SARCOMAS - SOUTHWEST ONCOLOGY GROUP-STUDY1979